Sign In
Buy TOVX
$0.288
+0.0020 (+0.699%)
At Close: Jun 03, 2026
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
08:15am, Thursday, 23'rd May 2024
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
08:00am, Tuesday, 14'th May 2024
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
07:00am, Tuesday, 07'th May 2024
- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the s
ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
–Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee–
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft –
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
08:00am, Monday, 08'th Apr 2024
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
12:01pm, Monday, 25'th Mar 2024
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
07:30am, Monday, 25'th Mar 2024
– The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Ade
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
08:00am, Tuesday, 19'th Mar 2024
ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
08:00am, Monday, 11'th Mar 2024
ROCKVILLE, Md., March 11, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024 The ind
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
08:00am, Tuesday, 16'th Jan 2024
ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disea
Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript
12:51pm, Friday, 17'th Nov 2023
Theriva Biologics, Inc. (NYSE:TOVX ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Steve Shallcross - Chief Executive and CFO Dr. Manel Cascalló - General Director
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
08:00am, Monday, 13'th Nov 2023
- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; mult
